This Article Full Text (OnlineFirst PDF) All Versions of this Article: 0269881108089806v1 23/3/278    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Müller, M. J. Articles by Hiemke, C. Search for Related Content PubMed PubMed Citation Articles by Müller, M. J. Articles by Hiemke, C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Psychotic Disorders Schizophrenia Social Bookmarking                         What's this?

Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder

¹ Department of Psychiatry, University of Mainz, Mainz, Germany; Clinic for Psychiatry and Psychotherapy, Marburg-Süd, Germany, and Clinic for Psychiatry and Psychotherapy, Giessen, Germany
² Sanofi-Aventis Deutschland GmbH, Berlin, Germany
³ Department of Psychiatry, University of Mainz, Mainz, Germany
⁴ Department of Psychiatry, University of Mainz, Mainz, Germany; Boehringer-Ingelheim, Biberach, Germany

^* To whom correspondence should be addressed.

	Abstract

Abstract

Because of a unique pharmacodynamic profile, amisulpride seems appropriate for treatment of elderly patients with schizophrenia. In a large-scale naturalistic therapeutic drug monitoring study, daily amisulpride dose, trough and dose-corrected amisulpride plasma levels, co-medication, clinical effectiveness (CGI) and side effects (UKU) were compared between age groups in 395 patients with schizophrenia or schizoaffective disorder (46% women; mean age 39.1 ± 14.2 years, range 18–83 years) under amisulpride therapy. Mean amisulpride doses (574 ± 269 mg/day), plasma levels (304 ± 274 ng/mL), dose-corrected amisulpride plasma levels (C/D ratios, 0.52 ± 0.41 ng/mL:mg), clinical response (at least moderate improvement, 71.6%), and side effects (any side effect, 32.2%; extrapyramidal symptoms, 14.9%) were comparable between age groups (P > 0.25). At higher age, significantly more benzodiazepines (P = 0.04), non-benzodiazepine hypnotics (P = 0.004) and non-psychotropic medications (P < 0.0001) were prescribed. The naturalistic study showed higher C/D ratios in women (P  slight increase of C/D ratios with age (P = 0.026), but no substantial age-dependent effects on amisulpride doses or plasma levels. In patients above 60 years, clinical response was associated with lower amisulpride plasma levels (P = 0.016) at comparable doses. Neither the age-dependent decrease of amisulpride clearance nor the significantly higher prevalence of co-morbidity and co-medication seem to be the reasons for definite clinical concerns against amisulpride treatment of elderly if contraindications are seriously taken.

Key Words: age, amisulpride, clinical treatment, plasma levels, schizophrenia

First published on June 18, 2008, doi:10.1177/0269881108089806

Journal of Psychopharmacology 2009;23:278.

A more recent version of this article appeared on May 1, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?